Law Firms Court Lead Plaintiffs in GeneDx Securities Suit After $31M Fabric Impairment

Overview

• GeneDx disclosed on May 4, 2026 a drop in adjusted gross margin, lowered 2026 guidance and a roughly $31.2–$31.3 million impairment tied to its April 2025 acquisition of Fabric Genomics.
• Plaintiffs allege GeneDx overstated Fabric’s benefits and hid viability problems that later required the large impairment and contributed to weaker reimbursement rates and margins.
• Multiple plaintiff firms have filed suits or issued notices and are soliciting investors who bought GeneDx stock between April 16, 2025 and May 4, 2026 to join the litigation and seek lead-plaintiff status by the August 3, 2026 deadline.
• No class has been certified and the cases are at an early procedural stage, but appointment of a lead plaintiff would likely trigger document discovery and depositions probing management’s knowledge and public statements.
• If the litigation advances, investors who suffered losses may pursue recovery through contingency-fee counsel, and the suits could sharpen scrutiny of M&A disclosures and product-mix reporting in the genetic testing sector.